Veracyte, Inc.

Veracyte, Inc. is a global cancer diagnostics company headquartered in South San Francisco, California, with additional offices in San Diego, Austin, Texas, and Haifa, Israel. The company's core business is to transform cancer care by providing genomic and molecular diagnostic tests that resolve diagnostic ambiguity and empower clinicians with high-value insights to guide patient treatment decisions. Its mission is to transform cancer care for patients worldwide.

Veracyte offers a portfolio of molecular tests across various cancer types and interstitial lung diseases. Key products include the Afirma Genomic Sequencing Classifier for thyroid cancer, the Decipher Prostate Genomic Classifier for prostate cancer, the Prosigna Breast Cancer Prognostic Gene Signature Assay for breast cancer, the Decipher Bladder Genomic Classifier for bladder cancer, and the TrueMRD monitoring test for minimal residual disease. The company provides laboratory developed tests (LDTs) through its CLIA-certified, high-complexity labs in the U.S. and offers in vitro diagnostics (IVD) services for international markets, alongside biopharmaceutical services.

Recent notable developments for Veracyte include the commercial launch of the Prosigna Breast Test in the U.S. in June 2026. Landmark clinical trials, such as ENZAMET and OPTIMA, have demonstrated the utility of Veracyte's Decipher Prostate and Prosigna tests in guiding chemotherapy decisions for prostate and breast cancer patients, respectively. The company also secured Medicare coverage for its TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer in May 2026. Veracyte reported strong financial performance in Q1 2026, with significant year-over-year increases in total revenue and net income. Marc Stapley serves as the Chief Executive Officer, having taken over from co-founder Bonnie Anderson in June 2021.